HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Montagut, C Articles by Albanell, J Search for Related Content PubMed PubMed Citation Articles by Montagut, C Articles by Albanell, J

¹ Medical Oncology Department, Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona 08035, Spain
² Medical Oncology Department, Hospital del Mar – IMAS, Barcelona 08003, Spain
³ Pathology Department, Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona 08035, Spain
⁴ Pathology Department, Hospital del Mar – IMAS, Barcelona 08003, Spain
⁵ Unitat de Recerca en Terapeutica Experimental del cancer (URTEC), Hospital de Mar–IMIM, Barcelona 08003, Spain

(Requests for offprints should be addressed to J Albanell; Email: JAlbanell{at}imas.imim.es)

The nuclear factor (NF)-B system is a promising anticancer target due to its role in oncogenesis and chemoresistance in preclinical models. To provide evidence in a clinical setting on the role of NF-B in breast cancer, we aimed to study the value of basal NF-B/p65 in predicting resistance to neoadjuvant chemotherapy, and to characterise the pharmacodynamic changes in NF-B/p65 expression following chemotherapy in patients with locally advanced breast cancer. Pre- and post-chemotherapy tumour specimens from 51 breast cancer patients treated with anthracycline- and/or taxane-containing neoadjuvant chemotherapy were assayed by immunohistochemistry for NF-B/p65 subcellular expression. We studied NF-B/p65, a well-characterised member of the NF-B family that undergoes nuclear translocation when NF-B is activated. Activation of NF-B (i.e. nuclear NF-B/p65 staining in pre-therapy specimens) was linked to chemoresistance. Patients with NF-B/p65 nuclear staining in pre-treatment samples had a 20% clinical response rate, while patients with undetected nuclear staining had a 91% response rate to chemotherapy (P = 0.002). Notably, four patients achieved a complete histological response and none of them had pre-treatment NF-B/p65 nuclear staining. Moreover, the number of patients with NF-B/p65 activation increased after chemotherapy exposure. It is concluded that NF-B/p65 activation assayed by immunohistochemistry is a predictive factor of resistance to neoadjuvant chemotherapy in breast cancer patients. Moreover, NF-B activation was inducible following chemotherapy in a proportion of breast cancer patients. These novel clinical findings strengthen the rationale for the use of NF-B inhibitors to prevent or overcome chemoresistance in breast cancer.